Share Name Share Symbol Market Type Share ISIN Share Description
Onzima Ventures LSE:ONZ London Ordinary Share GB00BYQCDH57 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1.25p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 0.0 -0.2 -2.3 - 2.27

Onzima Ventures (ONZ) Latest News

More Onzima Ventures News
Onzima Ventures Takeover Rumours

Onzima Ventures (ONZ) Share Charts

1 Year Onzima Ventures Chart

1 Year Onzima Ventures Chart

1 Month Onzima Ventures Chart

1 Month Onzima Ventures Chart

Intraday Onzima Ventures Chart

Intraday Onzima Ventures Chart

Onzima Ventures (ONZ) Discussions and Chat

Onzima Ventures Forums and Chat

Date Time Title Posts
21/11/201618:32Buy ONZ to get N4 Pharma's multi-blockuster potential528.00
11/11/201616:31Onzima - the old Ultima Networks 839.00
02/8/201617:26Large Healthcare Company28.00
02/8/201616:14Ј500m+ Company462.00
02/8/201615:55Ј2.6m mcap!16.00

Add a New Thread

Onzima Ventures (ONZ) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Onzima Ventures trades in real-time

Onzima Ventures (ONZ) Top Chat Posts

DateSubject
10/12/2016
08:20
Onzima Ventures Daily Update: Onzima Ventures is listed in the Software & Computer Services sector of the London Stock Exchange with ticker ONZ. The last closing price for Onzima Ventures was 1.25p.
Onzima Ventures has a 4 week average price of 0p and a 12 week average price of 1.31p.
The 1 year high share price is 1.90p while the 1 year low share price is currently 0p.
There are currently 181,956,558 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Onzima Ventures is £2,274,456.98.
29/7/2016
10:35
fido: Been a busy morning. Very quickly before I set off, many here say that onz can increase their stake in N4. However there are those who consider that onz are already in breach of their investment policy. Catch you later. Is Onzima Ventures breaching it's investing policy? By Gary Newman | Tuesday 8 March 2016 Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article. I’ve been noticing a lot of chatter on Twitter about a small AIM investing company called Onzima Ventures (ONZ), so I decided to take a closer look to see if all the fuss was justified! This company was previously known as Ultima Networks until October 15 last year when it changed its name, having disposed of all of its operating activities and then raised £750,000, before expenses, by issuing 107.1 million shares at 0.7p. Last week it saw its share price rocket when it announced that it had acquired a 49% stake in a private company called N4 Pharma Limited, via the issue of 24.27 million Onzima shares (locked in for two years) plus £41,000 in cash. On the face of it N4 Pharma looks quite interesting as it is in the biotech industry and reformulates existing drugs using it’s patented Cocrys and Nuvac technology platforms, plus founder Nigel Theobald has over 25 years in the industry. As part of the deal Onzima also agreed to provide a loan facility of £209,000 to develop the business, at an annual rate of 5% and repayable after four years, and there has been much excitement on the chat forums about how great N4 and it’s products are – although it is yet to actually have any product approved or ready for market. The main focus seems to be around a faster-acting alternative to existing Viagra, where the patent ran out in 2013, and there have been boasts about this market being potentially worth $4 billion. With that in mind I find it somewhat strange that N4 Pharma has had to turn to a tiny AIM company like Onzima to secure the funding that it needs, as you’d think that potential investors would be crawling all over it if the product was that good! It is hard to find that much information on N4 Pharma as it is privately listed, although its last accounts up to the end of March 2015 did show that it had trade creditors of over £52,000, with just £5,500 in the bank and net liabilities of nearly £37,000. This might suggest that it wasn’t in great financial shape, having only been set up a couple of years or so ago, yet Onzima has paid the equivalent of around £200,000 in cash and shares for it’s 49% stake. Given the costs often associated with biotech and getting a final drug to market, even if it is only in a new form, I have to wonder how much more cash it is going to need in the future, as well as whether bigger companies are going to just stand aside and allow it to grab a share of the Viagra market, or that of any other major drug for that matter! But what also interests me is whether Onzima is adhering to its investing policy, as set out when it changed it’s name and became an investing company. It raised net proceeds of £650,000 from the equity issue, which amounted to its net cash at the time, and its investing policy states that it will seek to invest a minimum of 75% of its deployable capital in the natural resources sector – an area it’s CEO Gavin Burnell (of Globo infamy) knows well from previous directorships in companies such as Magnolia Petroleum (MAGP), plus a number of current ones. Now I can’t help wondering if that leaves Onzima in breach of its investing policy, given that the money potentially loaned to N4 is no longer available to be invested as stated – although in terms of direct investment in N4 the company hasn’t breached the agreed 25% limit for non-natural resources based interests. Aside from this Onzima also invested £50,000 in fellow AIM investment company Glenwick (GWIK) at 0.1p back in December, and seems to have flipped that in circumstances which raised eyebrows (HERE). Onzima shares are currently trading at around 1.1p to buy and that gives a market cap of nearly £1.5 million, which represents a considerable mark-up to it’s actual asset value (given what it has paid for it’s share of N4 you would have to assume that is the current value of that 49% - although selling it to anyone else might not be easy so that is being generous!). There is also a £4 million debt technically due to the company as a result of the disposal of its previous assets, but any repayment of that will only benefit those holding special deferred shares, via any special dividend, which were issued when the capital was reorganised prior to the equity issue at 0.7p. This could well see further spikes in the future, but I would expect the majority of those to be based more on hype than substance, and therefore consider this company to be extremely high risk and not one for novice investors or small PIs to consider risking their money in. Even more so when I think there is the potential for questions to be raised about a possible breach of it’s investing criteria, plus the past few days are probably the first real chance that those 0.7p placees from back in October have had to offload at a profit, given very thin daily volumes for several months! - See more at: hTTp://www.shareprophets.com/views/19262/is-onzima-ventures-breaching-it-s-investing-policy#sthash.gZwJVm5r.dpuf
24/7/2016
20:02
bigego: Great post before K5000, it upset the nasty man! -------- keya5000 24 Jul'16 - 19:52 - 206 of 228 2 0 thoughts below of an associate who holds an interest in ONZ covers the near term drivers very well. We all know this depends on the success of N4 but the main man has been there and done it before. Good chance we will see history repeat itself. I asked Nigel Theobald why he left his previous company. He replied that he left because he thinks he can do better with n4. That's good enough for me. --------- I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’; its market leading Viagra brand (“Viagra XL”?!)) I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divisions, asset trading and business development (were only one long term investment to be made and held, I feel that the creation of the B.D. division would have been largely pointless); - our directors not having bought stock on the open market. Inside? So news on this front likewise has the potential to act as a significant share price driver for ONZ. I believe cash burn is currently circa £15k per month, so there’s ample leg room before any fundraise is required. Indeed, it would seem that the Asset Trading division is covering all corporate overheads!
24/7/2016
18:52
keya5000: thoughts below of an associate who holds an interest in ONZ covers the near term drivers very well. We all know this depends on the success of N4 but the main man has been there and done it before. Good chance we will see history repeat itself. I asked Nigel Theobald why he left his previous company. He replied that he left because he thinks he can do better with n4. That's good enough for me. --------- I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’; its market leading Viagra brand (“Viagra XL”?!)) I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divisions, asset trading and business development (were only one long term investment to be made and held, I feel that the creation of the B.D. division would have been largely pointless); - our directors not having bought stock on the open market. Inside? So news on this front likewise has the potential to act as a significant share price driver for ONZ. I believe cash burn is currently circa £15k per month, so there’s ample leg room before any fundraise is required. Indeed, it would seem that the Asset Trading division is covering all corporate overheads!
20/7/2016
06:42
keya5000: Great post from lse. GraphiteTech 5,112 posts Reasons to buy. From a respected source. Bits removed to protect the senders identity. Comments below are reasons to buy ONZ. I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’; its market leading Viagra brand (“Viagra XL”?!)) I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divis
20/7/2016
06:41
keya5000: GraphiteTech 5,112 posts Reasons to buy. From a respected source. Bits removed to protect the senders identity. Comments below are reasons to buy ONZ. I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’; its market leading Viagra brand (“Viagra XL”?!)) I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divis
20/7/2016
06:40
keya5000: From lse. GraphiteTech 5,112 posts Reasons to buy. From a respected source. Bits removed to protect the senders identity. Comments below are reasons to buy ONZ. I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’; its market leading Viagra brand (“Viagra XL”?!)) I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divis
01/6/2016
21:41
fido: Purchmeisner. I can confirm that ONZ are currently in a closed period so directors are not in a position to buy but with regard the buying by Nigel I would not put too much importance on it because directors are generally not renowned for their timing and knowing what I do about what`s happening within the company, now really isn`t a clever time to be buying the shares. I believe Nigel`s action in buying the shares is one of desperation in support of the company and not for any other investment reasoning. Even Nigel`s re tweet of the recent news article shows he is acting more like an investor than a company manager and is obviously concerned about the current situation with the share price. As I said right from the start, it is probably the intention to get the share price up to reduce the dilution of a placing and that just isn`t happening. As for the tweeters, they are day traders and not investors. They make their money by using others and are not long term investors in any sense of the word. In fact they are the investors worst nightmare because it is their constantly taking their money off the table that impedes any progress that could be made by the share price. In simple terms, investors are being milked and I don`t agree with the methods being used to fleece people.
23/5/2016
09:26
fido: tenniselbow. "the company will need to raise money and with a low share price it would have to be at a large discount." Finally someone with savvy saw the obvious. This is starting to pan out the way I said right from the start. To begin with we had a string of positive news flow designed to lift the share price so that they could get away with a fund raising at above the initial IP price. That plan of action has fallen flat on its face as people saw that ONZ was all hype and no substance. They are now in a position where they need to raise cash in a falling share price environment and the only way they would get institutional support would be to have a private placing at a substantial discount to todays price. The placing is going to be highly dilutive to present shareholders which is why I said yesterday that it is complete madness to invest here.
27/4/2016
08:52
fido: I said before that investors were only looking at the big story of N4 and not looking at ONZ. As I said before N4 could turn out to be just a story line if its technology fails to gain acceptance leaving ONZ dead in the water without sending out the begging bowl. In my opinion what ONZ are trying to do with all the positive spin of N4 is to try and get the share price to a point where they can get a placing away at a greater price than the 0.7p original placing price and they are using N4 to do it. In my opinion they will fail to do this as people see that there will be no return from N4 for three years. As things stand at the moment with the share price the likelyhood is that any placing is going to have to be below the original placing price to get it away and that is not going to be good for the share price given the heavy dilution this will cause.
06/4/2016
09:25
fido: People investing in ONZ at the moment are doing so blinkered. What they see is potential in N4 and are piling in on any positive news flow. However future potential is just that and the stock market does not credit any value to that until any revenues are near term. In fact the market was actually quite surprised how much ONZ paid for their 49% stake. So with any return from N4 being years away we are left with ONZ which is a tiny investment company with very limited capital that is just about to run out of money. Investors therefore are thinking of N4 but investing in ONZ. The market has failed to push the share price to a level that would avoid serious dilution to current shareholders because of initial investors selling out into any rise, so with ONZ about to run out of money you are left with the almost certain prospect of a private placing at a significant discount to the initial 0.7p placing price and that is not going to be good for the current share price.
Onzima Ventures share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20161210 12:47:39